Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma

被引:33
作者
Royston, Daniel J. [1 ]
Gao, Qi [2 ,3 ]
Nghia Nguyen [2 ,3 ]
Maslak, Peter [2 ,3 ]
Dogan, Ahmet [2 ,3 ]
Roshal, Mikhail [2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
MRD; Minimal residual disease; Multiple myeloma; Plasma cell disorder; Multiparameter flow cytometry; Single tube; 10-color; Validation; MULTIPLE-MYELOMA; LENALIDOMIDE; TRANSPLANTATION; DEXAMETHASONE; BORTEZOMIB; THERAPY;
D O I
10.1093/ajcp/aqw052
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Widespread adoption of recent recommendations for minimal residual disease (MRD) detection in myeloma has partly been impeded by a paucity of studies detailing multiparameter flow cytometry (MPF) assay validation. In response, we have validated a novel and efficient single-tube 10-color assay for MRD detection that incorporates the recently recommended plasma cell markers. Methods: Aspirate samples from 53 patients with plasma cell disorder were analyzed using a novel single-tube 10-color method. The limit of detection, precision of measurement, and linearity of measurement of our new assay were determined using serial dilution experiments. The stability of the new antibody cocktail and the viability/specificity of stained samples were evaluated using serial time course measurements. Results: There was a high degree of quantitative agreement between our new 10-color method and an established eight-color method. Four positive samples detected by the 10-color assay were below or at the limit of detection of the eight-color assay, confirming its high sensitivity. In two cases, subsequent revision of the International Myeloma Working Group Uniform Response Criteria was necessary. Conclusion: Adoption of our validated 10-color assay would enable clinical laboratories to satisfy current MRD recommendations without significantly increasing the demands on current workflow practices.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 20 条
[1]   Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment [J].
Anderson, Kenneth C. .
CLINICAL CANCER RESEARCH, 2011, 17 (06) :1225-1233
[2]   Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].
Attal, Michel ;
Lauwers-Cances, Valerie ;
Marit, Gerald ;
Caillot, Denis ;
Moreau, Philippe ;
Facon, Thierry ;
Stoppa, Anne Marie ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Garderet, Laurent ;
Decaux, Olivier ;
Leyvraz, Serge ;
Vekemans, Marie-Christiane ;
Voillat, Laurent ;
Michallet, Mauricette ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Roussel, Murielle ;
Leleu, Xavier ;
Mathiot, Claire ;
Payen, Catherine ;
Avet-Loiseau, Herve ;
Harousseau, Jean-Luc .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791
[3]   Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques [J].
Biran, Noa ;
Ely, Scott ;
Chari, Ajai .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) :368-378
[4]   High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].
Child, JA ;
Morgan, GJ ;
Davies, FE ;
Owen, RG ;
Bell, SE ;
Hawkins, K ;
Brown, J ;
Drayson, MT ;
Selby, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883
[5]   What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series [J].
Ely, Scott ;
Biran, Noa ;
Chari, Ajai .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) :379-388
[6]   Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity [J].
Flanders, Aaron ;
Stetler-Stevenson, Maryalice ;
Landgren, Ola .
BLOOD, 2013, 122 (06) :1088-1089
[7]   A GEIL Flow Cytometry Consensus Proposal for Quantification of Plasma Cells: Application to Differential Diagnosis Between MGUS and Myeloma [J].
Frebet, Elise ;
Abraham, Julie ;
Genevieve, Franck ;
Lepelley, Pascale ;
Daliphard, Sylvie ;
Bardet, Valerie ;
Amsellem, Sophie ;
Guy, Julien ;
Mullier, Francois ;
Durrieu, Francoise ;
Venon, Marie-Dominique ;
Leleu, Xavier ;
Jaccard, Arnaud ;
Faucher, Jean-Luc ;
Bene, Marie C. ;
Feuillard, Jean .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (03) :176-185
[8]   Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma [J].
Kumar, Shaji ;
Flinn, Ian ;
Richardson, Paul G. ;
Hari, Parameswaran ;
Callander, Natalie ;
Noga, Stephen J. ;
Stewart, A. Keith ;
Turturro, Francesco ;
Rifkin, Robert ;
Wolf, Jeffrey ;
Estevam, Jose ;
Mulligan, George ;
Shi, Hongliang ;
Webb, Iain J. ;
Rajkumar, S. Vincent .
BLOOD, 2012, 119 (19) :4375-4382
[9]   Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium [J].
Landgren, Ola ;
Gormley, Nicole ;
Turley, Danielle ;
Owen, Roger G. ;
Rawstron, Andy ;
Paiva, Bruno ;
Barnett, David ;
Arroz, Maria ;
Wallace, Paul ;
Durie, Brian ;
Yuan, Constance ;
Dogan, Ahmet ;
Stetler-Stevenson, Maryalice ;
Marti, Gerald E. .
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (12) :1159-1160
[10]   Minimal residual disease in multiple myeloma: bringing the bench to the bedside [J].
Mailankody, Sham ;
Korde, Neha ;
Lesokhin, Alexander M. ;
Lendvai, Nikoletta ;
Hassoun, Hani ;
Stetler-Stevenson, Maryalice ;
Landgren, Ola .
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) :286-U139